Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Child-Pugh Class B Clear all
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT02507765
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
Other · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Jul 21, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

NCT02201901
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Jul 21, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

OCR002-SP103 - Oral Immediate Release Study

NCT03846843
View directory record Official record
Conditions
Cirrhosis
Interventions
OCR-002 IR Oral Tablet, OCR-002 Oral Solution, OCR-002 IV Solution
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Jul 21, 2026, 9:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

NCT04136444
View directory record Official record
Conditions
Healthy Study Participants, Impaired Hepatic Function
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 21, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

NCT01846455
View directory record Official record
Conditions
Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions
2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Jul 21, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

NCT02128958
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
CF102, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Jul 21, 2026, 9:50 AM EDT
Terminated Phase 3 Interventional Results available

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

NCT02762266
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
Interventions
Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol
Radiation · Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 21, 2026, 9:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

NCT04497038
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
Cabozantinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 21, 2026, 9:50 AM EDT